CervoMed (CRVO) director and CEO’s spouse granted 8,150 stock options

Rhea-AI Filing Summary

CervoMed Inc. reported an insider equity award linked to its CEO and President, John J. Alam. The Form 4 shows a grant of stock options covering 8,150 shares of common stock at an exercise price of $2.91 per share, held indirectly through his spouse.

The options were granted to Dr. Sylvie Gregoire, a non-employee director and spouse of the reporting person. The filing states that Alam disclaims beneficial ownership of these securities. The underlying shares vest monthly over one year in substantially equal 1/12 increments, beginning on June 30, 2026, subject to Dr. Gregoire’s continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ALAM JOHN J

Role CEO & President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,150 shares (Indirect, By Spouse)

Footnotes (1)

1. Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date.

Key Figures

Option grant size: 8,150 shares Exercise price: $2.91 per share Expiration date: June 8, 2036 +3 more

6 metrics

Option grant size 8,150 shares Stock Option (Right to Buy) granted to director spouse

Exercise price $2.91 per share Conversion or exercise price of stock options

Expiration date June 8, 2036 Option award expiration

Shares underlying award 8,150 shares Common stock underlying the option award

Post-transaction option holdings 8,150 shares Total option shares following this transaction, held indirectly

Vesting schedule 1/12 monthly over 1 year Vesting starts June 30, 2026, subject to continued service

Key Terms

Stock Option (Right to Buy), non-employee director, Section 16, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

non-employee director financial

"a non-employee director of the Issuer"

Section 16 regulatory

"for purposes of Section 16 or for any other purpose"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

vesting financial

"underlying the award will vest on a monthly basis over a one-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALAM JOHN J

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$2.91	06/08/2026		A		8,150		(2)	06/08/2036	Common Stock	8,150	$0	8,150	I	By Spouse

Explanation of Responses:

1. Consists of an option to purchase shares of common stock granted to Sylvie Gregoire, PharmD., the Reporting Person's spouse and a non-employee director of the Issuer. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

2. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Dr. Gregoire's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CervoMed (CRVO) disclose in this Form 4?

CervoMed disclosed a grant of stock options for 8,150 shares of common stock to Dr. Sylvie Gregoire, a non-employee director and spouse of CEO John J. Alam, at a $2.91 exercise price.

Who received the CervoMed (CRVO) stock options reported in this filing?

The options were granted to Dr. Sylvie Gregoire, PharmD., a non-employee director of CervoMed and spouse of CEO John J. Alam. The filing notes that Alam disclaims beneficial ownership of these securities for Section 16 and other purposes.

How many CervoMed (CRVO) shares are covered by the reported stock options?

The reported stock option grant covers 8,150 shares of CervoMed common stock. Following the transaction, 8,150 option shares are shown as held indirectly, reflecting the full amount of this award to Dr. Sylvie Gregoire.

What is the exercise price and expiration date of the CervoMed (CRVO) options?

The stock options have an exercise price of $2.91 per share and an expiration date of June 8, 2036. These terms define the price Dr. Gregoire can pay and the latest date she can exercise the options.

How do the CervoMed (CRVO) options reported here vest over time?

The common stock underlying the option award vests monthly over one year in substantially equal 1/12 increments. Vesting begins on June 30, 2026, and continues each month, contingent on Dr. Gregoire’s continued service with the company.

Does CEO John J. Alam directly own the CervoMed (CRVO) option grant?

The filing states that the options are held by his spouse and that he disclaims beneficial ownership. It specifies that this should not be deemed an admission that he is the beneficial owner for Section 16 or any other purpose.